103195-35-3

Basic information

• Product Name: ethyl 8-aMino-4-oxo-4H-chroMene-2-carboxylate
• Synonyms: ethyl 8-aMino-4-oxo-4H-chroMene-2-carboxylate;8-Amino-4-oxo-4H-1-benzopyran-2-carboxylic acid ethyl ester;ethyl 8-amino-4-oxo-4H-chromene-2-carboxylate(WXG00429)
• CAS NO: 103195-35-3
• Molecular Formula: C₁₂H₁₁NO₄
• Molecular Weight: 233.22004
• Mol File: 103195-35-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.359
• CAS DataBase Reference: ethyl 8-aMino-4-oxo-4H-chroMene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 8-aMino-4-oxo-4H-chroMene-2-carboxylate(103195-35-3)
• EPA Substance Registry System: ethyl 8-aMino-4-oxo-4H-chroMene-2-carboxylate(103195-35-3)

Safety Data

• Hazardous Substances Data: 103195-35-3(Hazardous Substances Data)

Usage

General Description

Ethyl 8-amino-4-oxo-4H-chromene-2-carboxylate is a compound with the chemical formula C13H11NO4. It belongs to the class of organic compounds known as coumarins, which are aromatic compounds containing a benzene moiety fused to a 2-pyrone through a carbon-carbon bond. This chemical is commonly used in the pharmaceutical industry for the synthesis of various drugs due to its potential pharmacological properties. It also exhibits anti-inflammatory, antioxidant, and anticancer activities, making it a valuable compound for medical research and drug development. Additionally, it may have other potential uses in the fields of agriculture, industrial chemistry, and material science.

Upstream product

• 161369-33-1 8-nitro-2-methoxycarbonyl-4-oxo-4H-1-benzopyran 
• 110683-75-5 ethyl 8-nitro-4-oxo-4H-benzopyran-2-carboxylate 
• 182356-63-4 (Z)-2-Hydroxy-4-(2-hydroxy-3-nitro-phenyl)-4-oxo-but-2-enoic acid ethyl ester 
• 28177-69-7 2-hydroxy-3-nitroacetophenone 

Downstream Products

• 1443367-04-1 8-(4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic acid 
• 136450-08-3 ethyl 4-oxo-8-(4-(4-phenylbutoxy)benzamido)chromene-2-carboxylate 
• 1443367-31-4 4-oxo-8-(4-propoxybenzamido)-4H-chromene-2-carboxylic acid 
• 1443367-27-8 ethyl 4-oxo-8-(4-propoxybenzamido)-4H-chromene-2-carboxylate 
• 1443367-30-3 8-(4-(cyclopropylmethoxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 
• 1443366-70-8 ethyl 8-(4-bromobenzamido)-4-oxo-4H-chromene-2-carboxylate 
• 1443366-69-5 ethyl 8-(4-Methoxybenzamido)-4-oxo-4H-chromene-2-carboxylate 
• 1443366-68-4 ethyl 4-oxo-8-(4-(trifluoromethyl)benzamido)-4H-chromene-2-carboxylate 
• 1443366-67-3 ethyl 8-(4-methylbenzamido)-4-oxo-4H-chromene-2-carboxylate 
• 1443366-66-2 ethyl 8-(3-nitrobenzamido)-4-oxo-4H-chromene-2-carboxylate 
• 1443366-65-1 ethyl 8-(3-methylbenzamido)-4-oxo-4H-chromene-2-carboxylate 
• 1258763-55-1 ethyl 8-benzamido-4-oxo-4H-chromene-2-carboxylate 
• 1443366-59-3 ethyl 4-oxo-8-(2-phenylacetamido)-4H-chromene-2-carboxylate 
• 1443366-58-2 ethyl 8-(cyclohexanecarboxamido)-4-oxo-4H-chromene-2-carboxylate 

Relevant articles and documents

Malonic acid receptors with decarboxylative activity

The geometry and electronic properties of several malonic acids receptors are studied with a view to optimizing their decarboxylative activity.

Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators

Selective optimization of side activities (SOSA) offers an alternative entry to early drug discovery and may provide rapid access to bioactive new chemical entities with desirable properties. SOSA aims to reverse a drug's side activities through structural modification and to design out the drug's original main action. We identified a moderate side activity for the cysteinyl leukotriene receptor 1 (CysLT1R) antagonist pranlukast on the farnesoid X receptor (FXR). Systematic structural modification of the drug allowed remarkable optimization of its partial FXR agonism to sub-nanonmolar potency. The resulting FXR modulators lack any activity on CysLT1R and are characterized by high selectivity, high metabolic stability, and low toxicity. With their favorable in vitro profile, these SOSA-derived FXR modulators constitute a new FXR ligand chemotype that appears suitable for further preclinical evaluation.

PROCESS FOR PRODUCING CHROMONE COMPOUND

A process for producing a dicarboxylic acid compound represented by the formula (4): wherein R1 and R2 are the same or different and each represents lower alkyl and the wavy line indicates that this compound is the E- or Z-isomer or